Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs Dacarbazine in Metastatic Uveal Melanoma
NCT01551459Phase 2Completed
- Start
- Oct 2010
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in Uveal melanoma (UM) (2 arms). Primary endpoint: Progression Free Survival. Started Oct 2010; status: completed.
02
Drugs
sunitinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01551459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551459.